logo
Explore 290 Genitourinary Licensing Deals - Payment Terms, Trends, and SEC-Filed Contracts

Explore 290 Genitourinary Licensing Deals - Payment Terms, Trends, and SEC-Filed Contracts

Yahoo4 days ago
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "Genitourinary Collaboration and Licensing Deals 2016-2025" report has been added to ResearchAndMarkets.com's offering.
Fully revised and updated, the report provides details of 290 genitourinary deals from 2016 to 2025.Genitourinary Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genitourinary deals entered into by the worlds leading biopharma companies. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.The initial chapters of this report provide an orientation of genitourinary dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in genitourinary dealmaking.Chapter 3 covers the financial deal terms for deals signed in the genitourinary field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.Chapter 4 provides a review of the top 25 most active biopharma companies in genitourinary dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.Chapter 5 provides a comprehensive and detailed review of genitourinary deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.Chapter 6 provides a comprehensive directory of genitourinary deals listed by therapeutic target.The report also includes numerous table and figures that illustrate the trends and activities in genitourinary deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.Genitourinary Collaboration and Licensing Deals provides the reader with the following key benefits:
Understand deal trends since 2016
Browse genitourinary collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Genitourinary Collaboration and Licensing Deals includes:
Trends in genitourinary dealmaking in the biopharma industry
Overview of collaboration and licensing deal structure
Directory of genitourinary deal records covering pharmaceutical and biotechnology
The leading genitourinary deals by value
Most active genitourinary licensing dealmakers
Analyzing contract agreements allows due diligence of:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered: Chapter 1 - IntroductionChapter 2 - Trends in genitourinary dealmaking2.1. Introduction2.2. Genitourinary partnering over the years2.3. Genitourinary partnering by deal type2.4. Genitourinary partnering by industry sector2.5. Genitourinary partnering by stage of development2.6. Genitourinary partnering by technology type2.7. Genitourinary partnering by therapeutic indicationChapter 3 - Financial deal terms for genitourinary partnering3.1. Introduction3.2. Disclosed financials terms for genitourinary partnering3.3. Genitourinary partnering headline values3.4. Genitourinary deal upfront payments3.5. Genitourinary deal milestone payments3.6. Genitourinary royalty ratesChapter 4 - Leading genitourinary deals and dealmakers4.1. Introduction4.2. Most active in genitourinary partnering4.3. List of most active dealmakers in genitourinary4.4. Top genitourinary deals by valueChapter 5 - Genitourinary contract document directory5.1. Introduction5.2. Genitourinary partnering deals where contract document availableChapter 6 - Genitourinary dealmaking by therapeutic target6.1. Introduction6.2. Deals by genitourinary therapeutic targetDeal directoryDeal directory - Genitourinary deals by company A-Z 2016 to 2025Deal directory - Genitourinary deals by technology type 2016 to 2025Deal type definitions
For more information about this report visit https://www.researchandmarkets.com/r/jhxqgf
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sustainable Funds Rebound With Global Inflows of $4.9 Billion
Sustainable Funds Rebound With Global Inflows of $4.9 Billion

Bloomberg

time5 hours ago

  • Bloomberg

Sustainable Funds Rebound With Global Inflows of $4.9 Billion

The global market for sustainable funds recovered in the second quarter after posting record-high redemptions during the first three months of the year, according to an analysis by Morningstar Inc. Against a backdrop of 'ESG backlash and volatility sparked by geopolitical tensions and US tariffs, the picture for ESG funds improved last quarter,' led by investments in European-based offerings, said Hortense Bioy, head of sustainable investing research at Morningstar Sustainalytics.

KKR Faces EU Probe Into Information Provided in $26 Billion NetCo Acquisition
KKR Faces EU Probe Into Information Provided in $26 Billion NetCo Acquisition

Wall Street Journal

time5 hours ago

  • Wall Street Journal

KKR Faces EU Probe Into Information Provided in $26 Billion NetCo Acquisition

The European Union opened an investigation into whether KKR KKR 1.62%increase; green up pointing triangle supplied the block's merger regulator with false or misleading information before the investment firm's multibillion-dollar purchase of Telecom Italia TIT 0.72%increase; green up pointing triangle unit NetCo was unconditionally cleared by officials last year. The European Commission approved the companies' deal in May 2024, initially ruling that KKR's bid to snap up Telecom Italia's broadband network assets for up to 22 billion euros ($25.90 billion) wouldn't affect competition in Europe. The watchdog had said the merged company wouldn't be able to deteriorate the conditions for rivals' access to services due to long-term agreements that FiberCop—a joint venture between Telecom Italia and KKR—held with several companies.

China's JD.com in talks to buy Germany's Ceconomy electronics
China's JD.com in talks to buy Germany's Ceconomy electronics

Yahoo

time5 hours ago

  • Yahoo

China's JD.com in talks to buy Germany's Ceconomy electronics

Ceconomy, the parent company of German electronic retailers MediaMarkt and Saturn, has said it is in advanced talks about a takeover bid by Chinese e-commerce group is considering a cash offer of €4.60 ($5.41) for each ordinary share, Ceconomy said on Thursday. No legally binding agreements have been made yet, it emphasized. Ceconomy shares recently jumped more than 10% to just under €4.14. Since the beginning of the year, they have risen by around 58% amid ongoing takeover speculation. The Kellerhals family, which founded Ceconomy, remains the Dusseldorf-based company's largest shareholder, with a 29.2% stake. The Meridian Foundation holds an 11% stake, while the Haniel family group and Freenet hold 16.7% and 6.7% respectively. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store